|
1
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI
|
|
2
|
Maehira H, Miyake T, Iida H, Tokuda A,
Mori H, Yasukawa D, Mukaisho KI, Shimizu T and Tani M: Vimentin
expression in tumor microenvironment predicts survival in
pancreatic ductal adenocarcinoma: heterogeneity in fibroblast
population. Ann Surg Oncol. 26:4791–4804. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Andriulli A, Festa V, Botteri E, Valvano
MR, Koch M, Bassi C, Maisonneuve P and Sebastiano PD:
Neoadjuvant/preoperative gemcitabine for patients with localized
pancreatic cancer: A meta-analysis of prospective studies. Ann Surg
Oncol. 19:1644–1662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kato H, Usui M, Isaji S, Nagakawa T, Wada
K, Unno M, Nakao A, Miyakawa S and Ohta T: Clinical features and
treatment outcome of borderline resectable pancreatic head/body
cancer: A multi-institutional survey by the Japanese society of
pancreatic surgery. J Hepatobiliary Pancreat Sci. 20:601–610. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Angelo F, Antolino L, Farcomeni A,
Sirimarco D, Kazemi Nava A, De Siena M, Petrucciani N, Nigri G,
Valabrega S, Aurello P and Ramacciato G: Neoadjuvant treatment in
pancreatic cancer: Evidence-based medicine? A systematic review and
meta-analysis. Med Oncol. 34:852017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Satoi S, Yamaue H, Kato K, Takahashi S,
Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, et al: Role
of adjuvant surgery for patients with initially unresectable
pancreatic cancer with a long-term favorable response to
non-surgical anti-cancer treatments: Results of a project study for
pancreatic surgery by the Japanese society of
hepato-biliary-pancreatic surgery. J Hepatobiliary Pancreat Sci.
20:590–600. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motoi F, Satoi S, Honda G, Wada K, Shinchi
H, Matsumoto I, Sho M, Tsuchida A and Unno M; Study Group of
Preoperative therapy for Pancreatic cancer (PREP), : A single-arm,
phase II trial of neoadjuvant gemcitabine and S1 in patients with
resectable and borderline resectable pancreatic adenocarcinoma:
PREP-01 study. J Gastroenterol. 54:194–203. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Unno M, Motoi F, Matsuyama Y, Satoi S,
Toyama H, Matsumoto I, Aosasa S, Shirakawa H, Wada K, Fujii T, et
al: Neoadjuvant chemotherapy with gemcitabine and S-1 versus
upfront surgery for resectable pancreatic cancer: Results of the
randomized phase II/III Prep-02/JSAP05 trial. Ann Surg. April
16–2025.(Epub ahead of print). View Article : Google Scholar
|
|
9
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maehira H, Tsuji Y, Iida H, Mori H, Nitta
N, Maekawa T, Kaida S, Miyake T and Tani M: Estimated tumor blood
flow as a predictive imaging indicator of therapeutic response in
pancreatic ductal adenocarcinoma: Use of three-phase
contrast-enhanced computed tomography. Int J Clin Oncol.
27:373–382. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neesse A, Michl P, Frese KK, Feig C, Cook
N, Jacobetz MA, Lolkema MP, Buchholz M, Olive KP, Gress TM and
Tuveson DA: Stromal biology and therapy in pancreatic cancer. Gut.
60:861–868. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Neesse A, Bauer CA, Öhlund D, Lauth M,
Buchholz M, Michl P, Tuveson DA and Gress TM: Stromal biology and
therapy in pancreatic cancer: Ready for clinical translation? Gut.
68:159–171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wolff RA, Wang-Gillam A, Alvarez H, Tiriac
H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, et
al: Dynamic changes during the treatment of pancreatic cancer.
Oncotarget. 9:14764–14790. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamdy A, Ichikawa Y, Toyomasu Y, Nagata M,
Nagasawa N, Nomoto Y, Sami H and Sakuma H: Perfusion CT to assess
response to neoadjuvant chemotherapy and radiation therapy in
pancreatic ductal adenocarcinoma: Initial experience. Radiology.
292:628–635. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miles KA: Measurement of tissue perfusion
by dynamic computed tomography. Br J Radiol. 64:409–412. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ishida M, Fujii T, Kishiwada M, Shibuya K,
Satoi S, Ueno M, Nakata K, Takano S, Uchida K, Ohike N, et al:
Japanese classification of pancreatic carcinoma by the Japan
pancreas society: Eight edition. J Hepatobiliary Pancreat Sci.
31:755–768. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Koyasu S, Tsuji Y, Harada H, Nakamoto Y,
Nobashi T, Kimura H, Sano K, Koizumi K, Hamaji M and Togashi K:
Evaluation of tumor associated stroma and its relationship with
tumor hypoxia using dynamic contrast-enhanced CT and (18)F
misonidazole PET in murine tumor models. Radiology. 278:734–741.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Alvarez R, Musteanu M, Garcia-Garcia E,
Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A,
Rodriguez-Pascual J, et al: Stromal disrupting effects of
nab-paclitaxel in pancreatic cancer. Br J Cancer. 109:926–933.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang C, Xi W, Jiang J, Ji J, Yu Y, Zhu Z
and Zhang J: Metronomic chemotherapy remodel cancer-associated
fibroblasts to decrease chemoresistance of gastric cancer in nude
mice. Oncol Lett. 14:7903–7909. 2017.PubMed/NCBI
|
